Rohto Pharmaceutical Co Ltd
TSE:4527

Watchlist Manager
Rohto Pharmaceutical Co Ltd Logo
Rohto Pharmaceutical Co Ltd
TSE:4527
Watchlist
Price: 2 866 JPY 2.93% Market Closed
Market Cap: 676.9B JPY
Have any thoughts about
Rohto Pharmaceutical Co Ltd?
Write Note

Net Margin
Rohto Pharmaceutical Co Ltd

9.7%
Current
11%
Average
3.3%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
9.7%
=
Net Income
27.3B
/
Revenue
282.1B

Net Margin Across Competitors

Country JP
Market Cap 653.8B JPY
Net Margin
10%
Country FR
Market Cap 181.7B EUR
Net Margin
15%
Country UK
Market Cap 114.1B GBP
Net Margin
11%
Country IN
Market Cap 5.5T INR
Net Margin
17%
Country UK
Market Cap 34.9B GBP
Net Margin
11%
Country DE
Market Cap 27.8B EUR
Net Margin
8%
Country US
Market Cap 27B USD
Net Margin
1%
Country JP
Market Cap 3T JPY
Net Margin
5%
Country IN
Market Cap 1.1T INR
Net Margin
-3%
Country IN
Market Cap 903.7B INR
Net Margin
14%
Country US
Market Cap 9.9B USD
Net Margin
12%
No Stocks Found

Rohto Pharmaceutical Co Ltd
Glance View

Market Cap
653.8B JPY
Industry
Consumer products

Rohto Pharmaceutical Co Ltd., a company deeply rooted in the legacy of Japanese innovation, traces its beginnings to the late 19th century. Initially specializing in over-the-counter (OTC) medicines, it has adeptly expanded its reach to include skincare and healthcare products. The company’s journey from its inception was marked by a relentless pursuit of addressing the evolving needs of its consumer base, leveraging its expertise in pharmaceuticals and chemistry to create products that cater to health and wellness. Rohto's commitment to research and development has enabled it to pioneer unique formulations, effectively blending traditional practices with modern scientific advances. This strategy has allowed Rohto to establish a strong foothold not only in Japan but also in international markets, appealing to a broad demographic. The core of Rohto's business lies in its ability to commercialize its innovative solutions across various channels. The company generates revenue primarily through the sale of its diversified product lines, which include eye drops, dermatological creams, and other personal care products. Rohto’s strategic acquisitions and partnerships have also played a critical role in its growth, enabling it to expand its market presence and adapt to global health trends. The ability to anticipate and respond to consumer needs allows Rohto to maintain a robust product pipeline, ensuring consistent sales performance. Through its global distribution networks and focused marketing efforts, Rohto capitalizes on its brand reputation for quality and reliability, ensuring a steady stream of profits.

Intrinsic Value
3 201.93 JPY
Undervaluation 10%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
9.7%
=
Net Income
27.3B
/
Revenue
282.1B
What is the Net Margin of Rohto Pharmaceutical Co Ltd?

Based on Rohto Pharmaceutical Co Ltd's most recent financial statements, the company has Net Margin of 9.7%.